• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Heartware’s Q3 revenues jump 41 percent

Heartware’s Q3 revenues jump 41 percent

November 5, 2009 By MassDevice staff

Sequential revenues at HeartWare International Inc. grew 14.6 percent to $3.4 million during the three months ended Sept. 30.

The Framingham, Mass., manufacturer of militarized heart pumps began limited sales late last year, after receiving an investigational device exemption from U.S. regulators in Sept. 2008. That means a comparison year-over-year results is misleading, as total 2008 sales reached only $332,000.

The HeartWare Ventricular Assist System was approved for commercial sales throughout most of Europe in January.

HeartWare significantly narrowed both its operating and net losses during the third quarter, compared with the previous three months. It cut operating losses by roughly 41 percent, to $3.4 million from $5.8 million during the June quarter. Net losses, meanwhile, declined to $5.9 million from $6.8 million, a 16 percent improvement over the prior quarter.

Through the first nine months of 2009, the company had a total net loss of just under $19 million on $11.95 million in sales. HeartWare has spent about $10 million so far this year on research and development — making up about half of its 2009 net loss.

“We are making the necessary investments in our operating infrastructure, staffing and clinical trials so as to lay the foundation for our continued growth,” CEO Doug Godshall said in a statement.

HeartWare also sharply improved its cash position during the quarter, with $31.4 million in available funds on hand at the end of September. In August, the company completed a new financing package with institutional and individual investors, banking $29.8 million of the $60 million private placement soon after the Aug. 11 closing. The other half hit in late October, after shareholders overwhelmingly approved the deal.

HeartWare had less than $6 million in cash on hand at the end of June. The company also identified several of the new participants in the private placement earlier this week, including affiliates of T. Rowe Price, John Hancock and TD Investments and several private equity funds specializing in healthcare investments.

Filed Under: Business/Financial News, MassDevice Earnings Roundup

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy